| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 30 | 2023 | 414 | 8.320 |
Why?
|
| Dementia | 24 | 2021 | 453 | 7.590 |
Why?
|
| Nursing Homes | 24 | 2021 | 99 | 7.090 |
Why?
|
| Cholinergic Antagonists | 12 | 2021 | 58 | 6.690 |
Why?
|
| Urinary Bladder, Overactive | 8 | 2021 | 37 | 5.680 |
Why?
|
| Multiple Sclerosis | 8 | 2023 | 349 | 4.980 |
Why?
|
| Depression | 16 | 2020 | 1715 | 3.560 |
Why?
|
| Drug Utilization | 15 | 2017 | 179 | 3.060 |
Why?
|
| Homes for the Aged | 8 | 2017 | 24 | 2.830 |
Why?
|
| Psychotic Disorders | 10 | 2013 | 147 | 2.820 |
Why?
|
| Psychotropic Drugs | 14 | 2019 | 133 | 2.760 |
Why?
|
| United States | 90 | 2023 | 15433 | 2.750 |
Why?
|
| Drug Prescriptions | 16 | 2019 | 289 | 2.670 |
Why?
|
| Practice Patterns, Physicians' | 18 | 2023 | 1303 | 2.620 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 7 | 2017 | 274 | 2.380 |
Why?
|
| Paroxetine | 4 | 2017 | 34 | 2.260 |
Why?
|
| Muscarinic Antagonists | 7 | 2021 | 83 | 2.200 |
Why?
|
| Medicare | 17 | 2022 | 860 | 2.180 |
Why?
|
| Pneumonia | 5 | 2022 | 751 | 2.130 |
Why?
|
| Cholinesterase Inhibitors | 5 | 2022 | 110 | 2.060 |
Why?
|
| Ambulatory Care | 11 | 2021 | 554 | 2.030 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2023 | 410 | 1.970 |
Why?
|
| Prescription Drugs | 4 | 2023 | 64 | 1.920 |
Why?
|
| Central Nervous System Stimulants | 5 | 2017 | 225 | 1.870 |
Why?
|
| Polypharmacy | 7 | 2022 | 57 | 1.850 |
Why?
|
| Patient Readmission | 3 | 2022 | 548 | 1.640 |
Why?
|
| Health Care Surveys | 14 | 2021 | 430 | 1.640 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 167 | 1.610 |
Why?
|
| Machine Learning | 3 | 2023 | 319 | 1.610 |
Why?
|
| Aged | 88 | 2023 | 70117 | 1.610 |
Why?
|
| Accidental Falls | 4 | 2016 | 142 | 1.610 |
Why?
|
| Logistic Models | 24 | 2022 | 3441 | 1.590 |
Why?
|
| Parkinson Disease | 4 | 2020 | 708 | 1.540 |
Why?
|
| Fractures, Bone | 4 | 2016 | 291 | 1.490 |
Why?
|
| Cross-Sectional Studies | 27 | 2023 | 4314 | 1.480 |
Why?
|
| Retrospective Studies | 62 | 2024 | 37905 | 1.430 |
Why?
|
| Cognitive Dysfunction | 3 | 2020 | 333 | 1.420 |
Why?
|
| Cohort Studies | 28 | 2022 | 9244 | 1.370 |
Why?
|
| Office Visits | 5 | 2020 | 97 | 1.280 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2021 | 56 | 1.280 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 8 | 2022 | 598 | 1.260 |
Why?
|
| Humans | 147 | 2024 | 261506 | 1.230 |
Why?
|
| Fingolimod Hydrochloride | 3 | 2023 | 45 | 1.230 |
Why?
|
| Health Expenditures | 5 | 2023 | 211 | 1.180 |
Why?
|
| Medicaid | 13 | 2022 | 279 | 1.120 |
Why?
|
| Male | 92 | 2023 | 123000 | 1.120 |
Why?
|
| Hip Fractures | 2 | 2018 | 76 | 1.120 |
Why?
|
| Activities of Daily Living | 6 | 2022 | 552 | 1.100 |
Why?
|
| Medication Errors | 4 | 2015 | 174 | 1.090 |
Why?
|
| Female | 96 | 2023 | 141928 | 1.090 |
Why?
|
| Alzheimer Disease | 3 | 2023 | 855 | 1.080 |
Why?
|
| Analgesics, Opioid | 6 | 2024 | 1371 | 1.070 |
Why?
|
| Inappropriate Prescribing | 2 | 2015 | 50 | 1.040 |
Why?
|
| Aged, 80 and over | 43 | 2020 | 29902 | 1.030 |
Why?
|
| Heart Failure | 10 | 2023 | 2516 | 0.980 |
Why?
|
| Antidepressive Agents | 7 | 2017 | 332 | 0.970 |
Why?
|
| Medication Adherence | 6 | 2023 | 492 | 0.970 |
Why?
|
| Drug Therapy, Combination | 8 | 2023 | 2315 | 0.950 |
Why?
|
| Mental Disorders | 7 | 2019 | 862 | 0.890 |
Why?
|
| Quality of Life | 8 | 2022 | 4532 | 0.870 |
Why?
|
| Hospitalization | 12 | 2024 | 2083 | 0.850 |
Why?
|
| Risk | 12 | 2018 | 1972 | 0.820 |
Why?
|
| Adolescent | 38 | 2023 | 31252 | 0.820 |
Why?
|
| Cardiovascular Diseases | 4 | 2023 | 2195 | 0.810 |
Why?
|
| Potentially Inappropriate Medication List | 1 | 2021 | 12 | 0.800 |
Why?
|
| Mandelic Acids | 1 | 2020 | 3 | 0.760 |
Why?
|
| Urological Agents | 1 | 2020 | 6 | 0.760 |
Why?
|
| Asthma | 2 | 2019 | 871 | 0.760 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2021 | 177 | 0.750 |
Why?
|
| Benzofurans | 1 | 2020 | 38 | 0.740 |
Why?
|
| Cognition | 3 | 2023 | 968 | 0.730 |
Why?
|
| Withholding Treatment | 2 | 2020 | 161 | 0.730 |
Why?
|
| Pyrrolidines | 1 | 2020 | 113 | 0.720 |
Why?
|
| Biological Products | 1 | 2023 | 274 | 0.720 |
Why?
|
| Propensity Score | 9 | 2017 | 750 | 0.720 |
Why?
|
| Drug Therapy | 4 | 2008 | 205 | 0.720 |
Why?
|
| Drug Utilization Review | 3 | 2015 | 36 | 0.720 |
Why?
|
| Proportional Hazards Models | 14 | 2020 | 4988 | 0.710 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2021 | 226 | 0.700 |
Why?
|
| Prescriptions | 4 | 2024 | 65 | 0.680 |
Why?
|
| Comorbidity | 7 | 2020 | 2352 | 0.680 |
Why?
|
| Longitudinal Studies | 9 | 2021 | 1945 | 0.680 |
Why?
|
| Prevalence | 10 | 2021 | 3260 | 0.670 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 289 | 0.660 |
Why?
|
| Multivariate Analysis | 12 | 2016 | 4298 | 0.650 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 257 | 0.630 |
Why?
|
| Outpatients | 7 | 2023 | 462 | 0.630 |
Why?
|
| Residence Characteristics | 6 | 2019 | 348 | 0.620 |
Why?
|
| Osteoporotic Fractures | 1 | 2018 | 37 | 0.620 |
Why?
|
| Case-Control Studies | 10 | 2023 | 6100 | 0.610 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2019 | 118 | 0.600 |
Why?
|
| Myasthenia Gravis | 1 | 2018 | 99 | 0.600 |
Why?
|
| Proton Pump Inhibitors | 2 | 2019 | 249 | 0.590 |
Why?
|
| Documentation | 1 | 2019 | 207 | 0.590 |
Why?
|
| Bipolar Disorder | 6 | 2019 | 376 | 0.590 |
Why?
|
| Patient Discharge Summaries | 1 | 2016 | 9 | 0.580 |
Why?
|
| Cost of Illness | 1 | 2020 | 498 | 0.580 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 586 | 0.580 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2023 | 1039 | 0.580 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 36 | 0.570 |
Why?
|
| Patient Discharge | 2 | 2022 | 661 | 0.570 |
Why?
|
| Data Collection | 4 | 2013 | 620 | 0.560 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 945 | 0.550 |
Why?
|
| Socioeconomic Factors | 8 | 2019 | 1225 | 0.540 |
Why?
|
| Child | 32 | 2024 | 29154 | 0.530 |
Why?
|
| Adult | 27 | 2023 | 77950 | 0.520 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 544 | 0.520 |
Why?
|
| Health Status | 2 | 2015 | 590 | 0.510 |
Why?
|
| Disabled Persons | 1 | 2016 | 121 | 0.510 |
Why?
|
| Odds Ratio | 6 | 2021 | 2316 | 0.500 |
Why?
|
| Risk Adjustment | 1 | 2015 | 83 | 0.500 |
Why?
|
| Incidence | 10 | 2019 | 5673 | 0.490 |
Why?
|
| Linear Models | 4 | 2022 | 1085 | 0.460 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 285 | 0.460 |
Why?
|
| Age Factors | 9 | 2020 | 5377 | 0.460 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2017 | 32 | 0.450 |
Why?
|
| Dimethyl Fumarate | 2 | 2023 | 10 | 0.450 |
Why?
|
| Middle Aged | 28 | 2023 | 86204 | 0.450 |
Why?
|
| Risk Factors | 15 | 2020 | 17523 | 0.440 |
Why?
|
| Osteoarthritis | 1 | 2013 | 94 | 0.440 |
Why?
|
| Mortality | 1 | 2015 | 343 | 0.430 |
Why?
|
| Neurodegenerative Diseases | 1 | 2015 | 264 | 0.430 |
Why?
|
| Galantamine | 2 | 2022 | 11 | 0.430 |
Why?
|
| Rivastigmine | 2 | 2022 | 26 | 0.430 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2023 | 151 | 0.420 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 524 | 0.420 |
Why?
|
| Phenylcarbamates | 2 | 2022 | 25 | 0.410 |
Why?
|
| Health Services for the Aged | 1 | 2012 | 50 | 0.410 |
Why?
|
| Acetylcholinesterase | 2 | 2021 | 23 | 0.400 |
Why?
|
| Immunosuppressive Agents | 3 | 2023 | 1375 | 0.400 |
Why?
|
| Indans | 2 | 2022 | 68 | 0.400 |
Why?
|
| Joint Diseases | 1 | 2011 | 71 | 0.400 |
Why?
|
| Emergency Service, Hospital | 6 | 2024 | 1148 | 0.400 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 4320 | 0.400 |
Why?
|
| Home Care Services | 1 | 2012 | 92 | 0.390 |
Why?
|
| Depressive Disorder | 1 | 2015 | 557 | 0.390 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 622 | 0.390 |
Why?
|
| Cerebrovascular Disorders | 2 | 2010 | 142 | 0.380 |
Why?
|
| Healthcare Disparities | 5 | 2019 | 598 | 0.380 |
Why?
|
| Geography | 3 | 2019 | 140 | 0.370 |
Why?
|
| Methotrexate | 2 | 2023 | 999 | 0.360 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 761 | 0.360 |
Why?
|
| Off-Label Use | 1 | 2010 | 46 | 0.360 |
Why?
|
| Steroids | 1 | 2011 | 356 | 0.360 |
Why?
|
| Outpatient Clinics, Hospital | 3 | 2017 | 94 | 0.350 |
Why?
|
| Child Welfare | 1 | 2009 | 66 | 0.350 |
Why?
|
| Pediatrics | 1 | 2019 | 1141 | 0.350 |
Why?
|
| Drug Labeling | 1 | 2009 | 29 | 0.350 |
Why?
|
| Papillomavirus Vaccines | 1 | 2012 | 195 | 0.340 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 1085 | 0.330 |
Why?
|
| Drug Interactions | 3 | 2019 | 553 | 0.330 |
Why?
|
| Needs Assessment | 1 | 2009 | 233 | 0.320 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 461 | 0.320 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 68 | 0.320 |
Why?
|
| Treatment Outcome | 11 | 2023 | 32848 | 0.310 |
Why?
|
| Propylamines | 1 | 2007 | 12 | 0.310 |
Why?
|
| Hypertension | 3 | 2016 | 1503 | 0.290 |
Why?
|
| Young Adult | 10 | 2020 | 21445 | 0.290 |
Why?
|
| Piperidines | 2 | 2022 | 1035 | 0.280 |
Why?
|
| Health Services Needs and Demand | 4 | 2015 | 244 | 0.260 |
Why?
|
| Health Surveys | 3 | 2012 | 402 | 0.250 |
Why?
|
| Quality Assurance, Health Care | 2 | 2009 | 585 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 1209 | 0.240 |
Why?
|
| Crotonates | 1 | 2023 | 5 | 0.230 |
Why?
|
| Fees, Pharmaceutical | 1 | 2003 | 3 | 0.230 |
Why?
|
| Diabetes Mellitus | 2 | 2012 | 1054 | 0.230 |
Why?
|
| Atomoxetine Hydrochloride | 2 | 2017 | 16 | 0.230 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 441 | 0.230 |
Why?
|
| Time Factors | 6 | 2017 | 12926 | 0.220 |
Why?
|
| Papillomavirus Infections | 1 | 2012 | 980 | 0.220 |
Why?
|
| Lennox Gastaut Syndrome | 1 | 2022 | 15 | 0.220 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2022 | 28 | 0.220 |
Why?
|
| Pharmacists | 3 | 2000 | 95 | 0.220 |
Why?
|
| Medicare Part D | 2 | 2015 | 30 | 0.210 |
Why?
|
| Glatiramer Acetate | 1 | 2022 | 13 | 0.210 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2024 | 126 | 0.210 |
Why?
|
| Geriatrics | 1 | 2003 | 98 | 0.210 |
Why?
|
| Cannabidiol | 1 | 2022 | 42 | 0.210 |
Why?
|
| Benzodiazepines | 3 | 2012 | 170 | 0.210 |
Why?
|
| Managed Care Programs | 2 | 2019 | 74 | 0.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 521 | 0.200 |
Why?
|
| Anxiety | 4 | 2011 | 1179 | 0.200 |
Why?
|
| Sitagliptin Phosphate | 1 | 2021 | 5 | 0.200 |
Why?
|
| Tolterodine Tartrate | 1 | 2021 | 3 | 0.200 |
Why?
|
| Diltiazem | 1 | 2021 | 12 | 0.200 |
Why?
|
| Databases, Factual | 3 | 2016 | 2218 | 0.200 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2021 | 17 | 0.200 |
Why?
|
| Sotalol | 1 | 2021 | 31 | 0.200 |
Why?
|
| Citalopram | 1 | 2021 | 36 | 0.200 |
Why?
|
| Risk Assessment | 4 | 2016 | 6869 | 0.200 |
Why?
|
| Quality Indicators, Health Care | 1 | 2004 | 348 | 0.200 |
Why?
|
| Algorithms | 2 | 2023 | 3890 | 0.190 |
Why?
|
| Calcium Channel Blockers | 1 | 2021 | 135 | 0.190 |
Why?
|
| Aftercare | 1 | 2022 | 259 | 0.190 |
Why?
|
| Models, Economic | 2 | 2020 | 101 | 0.190 |
Why?
|
| Quetiapine Fumarate | 2 | 2012 | 16 | 0.190 |
Why?
|
| Dibenzothiazepines | 2 | 2012 | 13 | 0.190 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 5687 | 0.190 |
Why?
|
| Injections | 1 | 2021 | 285 | 0.180 |
Why?
|
| Thiazolidinediones | 1 | 2021 | 148 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 4938 | 0.180 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2022 | 181 | 0.180 |
Why?
|
| Schools, Pharmacy | 1 | 2019 | 22 | 0.180 |
Why?
|
| Pharmacy Service, Hospital | 2 | 1996 | 56 | 0.180 |
Why?
|
| Body Mass Index | 4 | 2023 | 2203 | 0.180 |
Why?
|
| Risperidone | 2 | 2012 | 62 | 0.180 |
Why?
|
| Glucocorticoids | 1 | 2023 | 629 | 0.180 |
Why?
|
| Area Under Curve | 1 | 2021 | 700 | 0.170 |
Why?
|
| Referral and Consultation | 1 | 2005 | 899 | 0.170 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2023 | 435 | 0.170 |
Why?
|
| Neoplasms | 2 | 2023 | 15193 | 0.170 |
Why?
|
| Hospitals | 1 | 2022 | 485 | 0.170 |
Why?
|
| Health Services Misuse | 1 | 1999 | 39 | 0.170 |
Why?
|
| Chronic Disease | 3 | 2020 | 1819 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 1362 | 0.170 |
Why?
|
| Geriatric Assessment | 1 | 2000 | 275 | 0.170 |
Why?
|
| Education, Pharmacy | 1 | 2019 | 50 | 0.170 |
Why?
|
| Weight Gain | 2 | 2019 | 464 | 0.160 |
Why?
|
| Sex Factors | 3 | 2015 | 2139 | 0.160 |
Why?
|
| Metformin | 1 | 2022 | 378 | 0.160 |
Why?
|
| Pain | 3 | 2024 | 1658 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2010 | 332 | 0.160 |
Why?
|
| Administration, Inhalation | 1 | 2019 | 285 | 0.160 |
Why?
|
| Vomiting | 1 | 1999 | 354 | 0.150 |
Why?
|
| Sinusitis | 1 | 2019 | 131 | 0.150 |
Why?
|
| Medical Errors | 1 | 2000 | 219 | 0.150 |
Why?
|
| Regression Analysis | 2 | 2015 | 1546 | 0.150 |
Why?
|
| Child Psychiatry | 1 | 2017 | 11 | 0.150 |
Why?
|
| Societies, Pharmaceutical | 1 | 1996 | 14 | 0.150 |
Why?
|
| Quality of Health Care | 2 | 2019 | 621 | 0.150 |
Why?
|
| Administration, Oral | 1 | 2021 | 1544 | 0.150 |
Why?
|
| Minority Groups | 1 | 2019 | 322 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 14889 | 0.140 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 334 | 0.140 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 98 | 0.130 |
Why?
|
| Medicare Part C | 1 | 2016 | 31 | 0.130 |
Why?
|
| Mental Health Services | 1 | 2018 | 227 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2020 | 674 | 0.130 |
Why?
|
| Causality | 1 | 2015 | 178 | 0.130 |
Why?
|
| Behavior | 1 | 2015 | 103 | 0.130 |
Why?
|
| Blood Glucose | 3 | 2023 | 1244 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 403 | 0.120 |
Why?
|
| Clostridium Infections | 1 | 2018 | 252 | 0.120 |
Why?
|
| Epilepsy | 1 | 2022 | 883 | 0.120 |
Why?
|
| Pharmaceutical Services | 2 | 2019 | 34 | 0.120 |
Why?
|
| Disability Evaluation | 1 | 2015 | 249 | 0.120 |
Why?
|
| Electronic Health Records | 2 | 2020 | 929 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2015 | 224 | 0.120 |
Why?
|
| Educational Status | 1 | 2015 | 397 | 0.120 |
Why?
|
| Child, Preschool | 5 | 2019 | 16273 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 672 | 0.110 |
Why?
|
| Research Design | 1 | 2020 | 1544 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2018 | 574 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2015 | 235 | 0.110 |
Why?
|
| Medical Records | 2 | 2007 | 415 | 0.110 |
Why?
|
| Peptic Ulcer | 2 | 2019 | 140 | 0.110 |
Why?
|
| Anti-Obesity Agents | 1 | 2012 | 30 | 0.110 |
Why?
|
| Models, Statistical | 2 | 2015 | 1171 | 0.110 |
Why?
|
| Foster Home Care | 1 | 2012 | 18 | 0.110 |
Why?
|
| Affect | 1 | 2014 | 288 | 0.110 |
Why?
|
| Delayed-Action Preparations | 1 | 2012 | 208 | 0.100 |
Why?
|
| Losartan | 1 | 2011 | 46 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 1756 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2023 | 323 | 0.100 |
Why?
|
| Valine | 1 | 2011 | 176 | 0.100 |
Why?
|
| Tetrazoles | 1 | 2011 | 106 | 0.100 |
Why?
|
| Arthritis | 1 | 2011 | 139 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2023 | 577 | 0.090 |
Why?
|
| Insurance Claim Reporting | 1 | 2010 | 17 | 0.090 |
Why?
|
| Infant | 4 | 2019 | 13310 | 0.090 |
Why?
|
| Physicians | 1 | 2019 | 882 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2015 | 717 | 0.090 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 194 | 0.090 |
Why?
|
| Amitriptyline | 2 | 2000 | 38 | 0.090 |
Why?
|
| Age Distribution | 1 | 2011 | 698 | 0.090 |
Why?
|
| Disease Progression | 1 | 2021 | 6682 | 0.090 |
Why?
|
| Legislation, Drug | 1 | 2009 | 17 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 482 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 395 | 0.090 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1274 | 0.080 |
Why?
|
| Social Class | 1 | 2010 | 310 | 0.080 |
Why?
|
| Financing, Personal | 1 | 2008 | 19 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2010 | 497 | 0.080 |
Why?
|
| Social Behavior | 1 | 2010 | 306 | 0.080 |
Why?
|
| Canada | 1 | 2009 | 429 | 0.080 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 41 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2011 | 428 | 0.080 |
Why?
|
| Prognosis | 2 | 2023 | 21713 | 0.080 |
Why?
|
| Texas | 4 | 2019 | 6311 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 849 | 0.080 |
Why?
|
| Demography | 2 | 1999 | 435 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 4892 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2007 | 756 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2019 | 8223 | 0.070 |
Why?
|
| Parents | 1 | 2012 | 998 | 0.060 |
Why?
|
| Life Style | 1 | 2008 | 612 | 0.060 |
Why?
|
| Primary Health Care | 2 | 2021 | 787 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2008 | 369 | 0.060 |
Why?
|
| Drug Approval | 1 | 2005 | 178 | 0.060 |
Why?
|
| Isosorbide Dinitrate | 1 | 2023 | 4 | 0.060 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2023 | 30 | 0.060 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2006 | 340 | 0.060 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2003 | 13 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 866 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 748 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 4757 | 0.060 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2024 | 108 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 830 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2004 | 333 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2008 | 1467 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2023 | 218 | 0.050 |
Why?
|
| Analgesics | 1 | 2024 | 390 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 378 | 0.050 |
Why?
|
| Utilization Review | 1 | 2000 | 48 | 0.050 |
Why?
|
| Cholesterol | 1 | 2023 | 658 | 0.050 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2000 | 91 | 0.050 |
Why?
|
| Physicians, Family | 1 | 2000 | 54 | 0.050 |
Why?
|
| Anti-Anxiety Agents | 1 | 2000 | 90 | 0.050 |
Why?
|
| Louisiana | 2 | 1996 | 139 | 0.050 |
Why?
|
| Dextropropoxyphene | 1 | 1999 | 7 | 0.040 |
Why?
|
| Chlordiazepoxide | 1 | 1999 | 3 | 0.040 |
Why?
|
| Pharmacy | 1 | 2019 | 15 | 0.040 |
Why?
|
| Obesity | 1 | 2012 | 2884 | 0.040 |
Why?
|
| Diazepam | 1 | 1999 | 39 | 0.040 |
Why?
|
| Dipyridamole | 1 | 1999 | 33 | 0.040 |
Why?
|
| Deprescriptions | 1 | 2019 | 24 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2022 | 431 | 0.040 |
Why?
|
| Students, Pharmacy | 1 | 2019 | 54 | 0.040 |
Why?
|
| Health Services Research | 1 | 2000 | 233 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 135 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 15694 | 0.040 |
Why?
|
| Contraindications | 1 | 1997 | 150 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 1998 | 183 | 0.040 |
Why?
|
| Emergencies | 1 | 1998 | 202 | 0.040 |
Why?
|
| Leadership | 1 | 2019 | 254 | 0.040 |
Why?
|
| Seizures | 1 | 2022 | 989 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 1996 | 45 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 59536 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 1000 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 1997 | 980 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 1293 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1996 | 1323 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 2518 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 625 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2012 | 78 | 0.030 |
Why?
|
| Models, Structural | 1 | 2011 | 103 | 0.030 |
Why?
|
| Fosinopril | 1 | 2011 | 5 | 0.030 |
Why?
|
| Valsartan | 1 | 2011 | 38 | 0.030 |
Why?
|
| Lisinopril | 1 | 2011 | 24 | 0.030 |
Why?
|
| Enalapril | 1 | 2011 | 20 | 0.030 |
Why?
|
| Captopril | 1 | 2011 | 34 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 126 | 0.020 |
Why?
|
| Veterans | 2 | 2011 | 1641 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2012 | 605 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 70 | 0.020 |
Why?
|
| Survival Rate | 2 | 2019 | 12221 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 6009 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 1997 | 66 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 12873 | 0.010 |
Why?
|
| Health Services | 1 | 1997 | 105 | 0.010 |
Why?
|